Peripheral neuropathies associated with levodopa-carbidopa continuous intestinal gel infusion: long-term prospective assessment

Authors: Andrea Bernardini, Alberto Romagnolo, Aristide Merola, Maurizio Zibetti, Dario Cocito, Leonardo Lopiano
Department of Neuroscience, University of Turin, via Cherasco 15, Turin

**Introduction:** levodopa-carbidopa intestinal gel infusion (LCIG) is an effective treatment for advanced Parkinson's disease (PD) [1]. Peripheral neuropathy (PN) is a described complication of LCIG infusion, and both subacute and chronic forms have been reported [1-3]. Although prospective analyses are required to investigate the role of LCIG in the pathogenesis of PN, only few data are currently available [4].

**Objectives:** to prospectively evaluate the incidence of PN during LCIG treatment.

**Methods:** 33 consecutive PD patients underwent a battery of PN-specific scales (ONLS, INCAT-SSS, MRCSS), nerve conduction studies and a serum work-up including vitamin B12, folate and homocysteine. The assessment was performed before starting LCIG infusion and regularly thereafter. Only subjects with normal clinical-electrophysiological (EP) features at baseline were included in the long-term analysis.

**Results:** at baseline 9% (3/33) patients showed a symptomatic sensory-motor PN and 21% (7/33) showed asymptomatic EP alterations (subclinical PN).

Over a follow-up of 24.36 ± 12.18 months, among patients with normal clinical and electrophysiological features at baseline, 8.7% (2/23) subjects developed a subacute PN, 8.7% (2/23) developed a chronic PN and 30.4% (7/23) developed a subclinical PN. The onset of subacute PN was significantly more precocious compared to other PN phenotypes (p: 0.001). All patients who developed PN received folate, vitamin B1 and vitamin B12 supplementations; only subacute PN patients required LCIG suspension.

Patients with subacute or subclinical PN showed no significant differences in B12, folate, homocysteine or levodopa-equivalent daily dose (LEDD) variations over time compared to patients without clinical-EP alterations. On the contrary, patients who developed chronic PN showed a higher increase in homocysteine (p: 0.024) and LEDD (p: 0.041) compared to normal patients (Figure 1), while no differences in vitamin B12 or folate levels were observed.

A progressive body mass index (BMI) decrease compared to baseline was observed both in chronic PN subjects (from 26.9 ± 5.3 to 24.5 ± 5.2; p: 0.049) and in normal subjects (from 23.6 ± 2.7 to 21.9 ± 2.0; p: 0.045). The modification of BMI over time did not show significant differences between groups (Figure 1).

Patients with symptomatic PN at baseline showed a mild EP worsening. 1/7 patients (14.3%) with subclinical PN at baseline developed a symptomatic PN after 12 months of LCIG infusion, associated with a marked weight loss; folate and vitamin B12 supplementations were administered and subsequent evaluations showed a substantial clinical and electrophysiological stability.

**Conclusion:** PN is a relevant complication among PD patients undergoing LCIG [2,3]: follow-up protocols should include serial clinical-electrophysiological evaluations [3]. The pathogenesis of subacute PN might be related to immunological triggers on predisposed subjects. On the contrary, higher LEDD and homocysteine-mediated neurotoxicity could be implicated in chronic forms [5]. Weight loss seems not to represent a primary causative factor of PN.

**References:**


